LabCorp Completes Acquisition of LIPOSCIENCE
November 21 2014 - 8:45AM
Business Wire
Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:
LH) today announced the completion of its acquisition of
LIPOSCIENCE, Inc. (NASDAQ:LPDX), effective November 20, 2014.
At a special meeting held on November 20, 2014, LIPOSCIENCE’s
stockholders approved the acquisition and the transaction closed
promptly thereafter. After the close of the Nasdaq Global Market on
November 20, 2014, trading in LIPOSCIENCE common stock ceased, and
the listing of LIPOSCIENCE’s common stock was suspended.
LIPOSCIENCE stockholders will receive a letter of transmittal from
Computershare Trust Company, N.A. as paying agent with instructions
on how to cash in their shares of LIPOSCIENCE common stock.
About LabCorp®
Laboratory Corporation of America® Holdings, an S&P 500
company, is a pioneer in commercializing new diagnostic
technologies and the first in its industry to embrace genomic
testing. With annual revenues of $5.8 billion in 2013, over 34,000
employees worldwide, and more than 220,000 clients, LabCorp offers
more than 4,000 tests ranging from routine blood analyses to
reproductive genetics to companion diagnostics. LabCorp furthers
its scientific expertise and innovative clinical testing technology
through its LabCorp Specialty Testing Group: The Center for
Molecular Biology and Pathology, National Genetics Institute,
ViroMed Laboratories, Inc, The Center for Esoteric Testing,
Litholink Corporation, Integrated Genetics, Integrated Oncology,
Dianon Pathology, Monogram Biosciences, Inc, Colorado Coagulation,
Cellmark Forensics, MedTox, and Endocrine Sciences. LabCorp
conducts clinical trials testing through its LabCorp Clinical
Trials division. LabCorp clients include physicians, government
agencies, managed care organizations, hospitals, clinical labs, and
pharmaceutical companies. To learn more about our organization,
visit our website at: www.labcorp.com.
This press release contains forward-looking statements including
with respect to estimated 2014 guidance and the impact of various
factors on operating results. Each of the forward-looking
statements is subject to change based on various important factors,
including without limitation, competitive actions in the
marketplace and adverse actions of governmental and other
third-party payers. Actual results could differ materially from
those suggested by these forward-looking statements. Further
information on potential factors that could affect LabCorp’s
operating and financial results is included in the Company’s Form
10-K for the year ended December 31, 2013, including under the
heading risk factors, and in the Company’s other filings with the
SEC. The information in this press release should be read in
conjunction with a review of the Company’s filings with the SEC
including the information in the section of the Company’s Form 10-K
for the year ended December 31, 2013 and subsequent Forms 10-Q
under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS.
LabCorp®Investor/Media Contact:Stephen Anderson,
336-436-5076Company Information: www.labcorp.com
(MM) (NASDAQ:LPDX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:LPDX)
Historical Stock Chart
From Jul 2023 to Jul 2024